Market Trends of Antibody Drug Conjugates Industry
Breast Cancer Segment accounted for the Largest Share of the Market
- The breast cancer segment is expected to witness significant growth over the forecast period due to the rising incidences of breast cancer worldwide. In addition, the growing product approvals and launches and ongoing clinical trials for breast cancers using Antibody Drug Conjugates contribute to ADC market growth over the forecast period.
- The success of Antibody Drug Conjugate in breast cancer has led to many new clinical studies in the field of Precision Oncology that are likely to boost the market's growth. For instance, the study published in the Journal of Cancer Research in February 2022 reported the most promising new ADC, which appears to be the TROP2-directed datopotamab deruxtecan, has shown encouraging early-phase activity in advanced relapsed/refractory HER2-negative breast cancer.
- Similarly, in March 2023, Ambrx Biopharma Inc. was informed by its partner, NovoCodex Biopharmaceuticals, Inc., that an interim analysis for ACE-Breast-02, a randomized Phase 3 breast cancer clinical trial investigating Ambrx's ARX788, an anti-HER2 Antibody Drug Conjugate (ADC), has met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater progression-free survival (PFS) benefit compared to the active control. Thus, such clinical trials are leading to the development of better Targeted Cancer Therapeutics for the treatment of breast cancer.
- The new approvals and launches of ADC for breast cancers increase the demand for this drug, which likely boosts the segment growth over the study period. For instance, in February 2023, Gilead Sciences, Inc. received approval from the United States Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
- Thus, the increasing R&D for breast cancer treatment and product approvals are anticipated to increase the use of Antibody Drug Conjugates in the treatment of breast cancer, boosting the Antibody Drug market and thus enhancing the segment's growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Witness Significant Growth Over the Forecast Period
- North America is expected to witness significant growth over the forecast period due to rising cancer cases and technological developments. The region is observing significant growth due to technological advancements, the local presence of key players, and strategic initiatives by leaders in countries such as the United States and Canada. In April 2021, Pfizer acquired Amplyx Pharmaceuticals Inc. to develop Antibody Drug Conjugates and several other therapies for cancer.
- North American countries are marked by high cancer cases. The increasing number of cancer cases is driving the growth of the market in the region. For instance, according to the 2021 and 2023 statistics published by the American Cancer Society (ACS), the incidence of cancer cases is estimated to increase from 1.91 million in 2021 to 1.96 million in 2023, an increase of more than 60 thousand cases in just two years, demonstrating a rapid increase in the incidence of cancer cases in the country. The chance of an increase in the incidence of cancer is likely to be high in the country, thus raising the demand for advanced oncology treatment, which ultimately boosts the Global ADC market growth.
- Antibody Drug Conjugate companies are expanding their portfolios with partnerships and new product approvals, which are expected to have significant impact on the market growth. For instance, in February 2023, Corbus Pharmaceuticals Holdings, Inc. entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited, for the development and commercialization of CRB-701 (SYS6002). The agreement covers exclusive commercialization rights to CRB-701 in the United States and Canada. In addition, in February 2022, Adcentrx Therapeutics and AvantGen entered a three-year, multi-target partnership for the discovery of antibodies to be developed into novel Antibody Drug Conjugate therapeutic candidates.
- Thus, owing to the growing number of cancer cases and strategic partnerships among the key players, along with regulatory approvals, the North American Antibody Drug Conjugates market is expected to grow significantly during the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
